NEWS
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Vaccinex (VCNX) has reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in early-stage Alzheimer's disease (AD). The study showed a statistically significant difference (p=0.0297) in FDG-PET signal in the medial temporal cortex after 12 months of treatment compared to placebo. Pepinemab was well-tolerated in AD patients.
Key findings include:
Reduction in blood levels of GFAP (astrocyte reactivity marker) and p-tau 217 (neuronal damage marker) in patients with Mild Cognitive Impairment (MCI) due to AD
Apparent slowing of cognitive decline in MCI patients, as measured by iADRS and ADAS-Cog 13 assessments
No discernible effect on biomarkers or cognitive decline in patients with early dementia
Vaccinex aims to pursue a development partnership for continued research in AD and other neurodegenerative diseases, including Huntington's Disease.
Vaccinex (VCNX) has reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in early-stage Alzheimer's disease (AD). The study showed a statistically significant difference (p=0.0297) in FDG-PET signal in the medial temporal cortex after 12 months of treatment compared to placebo. Pepinemab was well-tolerated in AD patients.
Key findings include:
Reduction in blood levels of GFAP (astrocyte reactivity marker) and p-tau 217 (neuronal damage marker) in patients with Mild Cognitive Impairment (MCI) due to AD
Apparent slowing of cognitive decline in MCI patients, as measured by iADRS and ADAS-Cog 13 assessments
No discernible effect on biomarkers or cognitive decline in patients with early dementia
Vaccinex aims to pursue a development partnership for continued research in AD and other neurodegenerative diseases, including Huntington's Disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment